| 1 |
Ettinger DS, Akerly W, Bepler G, et al. Non-small cell lung cancer[J]. Natl Compr Cancer Net, 2010 (7): 740-801.
|
| 2 |
Delbaldo C, Michiels S, Rolland E, et al. WITHDRAWN: second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease[J]. Cochrane Database Syst Rev, 2012 (4): CD004569.
|
| 3 |
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol, 2010, 11 (6): 521-529.
|
| 4 |
Sequist L, Yang J, Yamamoto N, et al. Phase Ⅲ study of aftinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with epidermal growth factor receptor mutations[J]. J Clin Oncol, 2013, 31 (27): 3327-3334.
|
| 5 |
Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase Ⅲ study of afatinib (A) vs. gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung[J]. Eur Resp J, 2013 (42): 371.
|
| 6 |
Yang J, Ramalingam SS, Janne PA, et al. LBA2_PR: osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated phase 1 (P1) and pooled phase 2 (P2) results[J]. J Thorac Oncol, 2016, 11 (4 Suppl): S152-S153.
|
| 7 |
Karlovich C, Goldman JW, Sun JM, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686)[J]. Clin Cancer Res, 2016, 22 (10): 2386-2395.
|
| 8 |
Priker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patient with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase Ⅲ trial[J]. Lancet, 2009, 373 (9674): 1525-1531.
|
| 9 |
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer[J]. N Engl J Med, 2010, 363 (18): 1693-1703.
|
| 10 |
Shaw AT, Kim DW, Mehra R, T, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 370 (13): 1189-1197.
|
| 11 |
Gridelli C, Rossi A, Ciardiello F, et al. BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2016, 17 (5): 461-465.
|
| 12 |
Kozuki T, Nogami N, Kitajima H, et al. Feasibility study of first-line chemotherapy using pemetrexed and bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015[J]. BMC Cancer, 2016 (16): 306.
|
| 13 |
Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial[J]. Lancet, 2014, 384 (9944): 665-673.
|
| 14 |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373 (2): 123-135.
|
| 15 |
Gatzemeier U, Groth G, Butts CV, et al. Randomized phase Ⅱ trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer[J]. Ann Oncol, 2004, 15 (1): 19-27.
|
| 16 |
Paz-Ares L, Hirsh V, Zhang L, et al. MISSION trial- a phase Ⅲ, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens[J]. J Thorac Oncol, 2015, 10 (12): 1745.
|
| 17 |
Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase Ⅱ, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens[J]. J Thorac Oncol, 2010, 5 (10): 1630.
|
| 18 |
Ohe Y. Chemoradiotherapy for lung cancer current status and perspective[J]. Int J Clin Oncol, 2004, 9 (6): 435-443.
|
| 19 |
Sayed MM, EI-Sayed MI, Abdel-Wanis ME, et al. Definitive chemoradiation for non-small-cell lung cancer: could a consensus be reached?[J]. Tumori, 2016, 102 (5): 496-500.
|
| 20 |
王劲，陆远强. 生活方式的改进与安全社区的构建[J/CD]. 中华危重症医学杂志（电子版），2013，6(3):132-133.
|